Susquehanna International Group’s Briacell Therapeutics BCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-489
Closed -$83.7K 11974
2024
Q2
$83.7K Sell
489
-394
-45% -$111K ﹤0.01% 11139
2024
Q1
$379K Buy
883
+2
+0.2% +$1.1K ﹤0.01% 9151
2023
Q4
$773K Buy
881
+456
+107% +$327K ﹤0.01% 7619
2023
Q3
$398K Buy
425
+302
+246% +$296K ﹤0.01% 8756
2023
Q2
$118K Sell
123
-5,842
-98% -$5.77M ﹤0.01% 10810
2023
Q1
$6.67M Buy
5,965
+1,329
+29% +$1.38M ﹤0.01% 3022
2022
Q4
$3.04M Buy
4,636
+602
+15% +$510K ﹤0.01% 4003
2022
Q3
$3.4M Sell
4,034
-1,566
-28% -$1.57M ﹤0.01% 3822
2022
Q2
$4.85M Buy
5,600
+716
+15% +$708K ﹤0.01% 3239
2022
Q1
$7.43M Buy
4,884
+685
+16% +$811K ﹤0.01% 2976
2021
Q4
$5.22M Buy
+4,199
New +$5.5M ﹤0.01% 3674

Other funds holding BCTX

Susquehanna International Group's BCTX Position: Q1 2025 in Review

Susquehanna International Group sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 337 shares — an estimated $28.6K sold.

Susquehanna International Group first reported a position in BCTX in Q1 2023 and held it in 8 quarters. The position peaked at $365K in Q4 2023. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • Susquehanna International Group reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 337 Briacell Therapeutics shares in Q1 2025, an estimated $28.6K.
  • Susquehanna International Group first reported a position in Briacell Therapeutics in Q1 2023 and held it in 8 quarters.
  • Susquehanna International Group's Briacell Therapeutics position peaked at $365K in Q4 2023.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.